Du sökte efter: expreS2ion
ExpreS2ion vill testa ES2B-C001 tillsammans med antikroppskonjugat
ExpreS2ion Biotech har ansökt om att ändra protokollet för sin fas I-studie av bröstcancervaccinet ES2B-C001 för att testa det...
Ännu ett lyckat Summit – se alla videos här
Den 20-21 november bjöd vi för sjunde gången in till BioStock Life Science Summit och nu kan du se...
BioStock träffar branschexperter på BIO-Europe
Partneringeventet BIO-Europe har varit ett viktigt nav för life science-branschens aktörer, både för kunskapsutbyte och nätverkande i tre decennier....
ExpreS2ion CEO talking about partnering efforts at BIO-Europe
Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also,...
Investing in life science: From Seed to Success 2024
Förra veckan samlades investerare och entreprenörer på World Trade Center i Stockholm för "Investing in Life Science: From Seed...
Rights issue takes Expres2ion breast cancer vaccine to phase I
Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer. A SEK...
ExpreS2ion CEO: “Compelling preclinical package gives us confidence”
Based on its proprietary protein expression platform, ExpreS2ion Biotech advances its ES2B-C001 breast cancer vaccine candidate toward clinical studies....
BioStock Global Forum 2024
On May 29-30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing...
Nyhetssvepet onsdag 5 april
Det senaste från BioStock
ExpreS2ion CEO comments ongoing rights issue
ExpreS2ion Biotechnologies has a broad portfolio of vaccine candidates based on its ExpreS2 platform. Right now, the company is...
BioStock Investor Pitch: ExpreS2ion Biotechnologies
Danish ExpreS2ion Biotechnologies develops a portfolio of vaccines currently targeting Covid-19, breast cancer, influenza, malaria and, with the latest...
Multiple near-term milestones for ExpreS2ion Biotechnologies
With an upcoming phase III readout and ongoing toxicology studies it is safe to say that ExpreS2ion Biotechnologies has...